Delcath Systems Technology Profiled in European Medical Technology Publication.NEW YORK New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of -- Delcath Systems, Inc. (Nasdaq:DCTH) announced today that the Company's high dose percutaneous perfusion technology for delivery of therapeutic and chemotherapeutic agents This is a list of specific pharmacologic agents that are known to be of use in the treatment of cancer, otherwise known as chemotherapeutic agents. This list is organized by "type" of agent, though the subsections are not necessarily definitive and are subject to revision. to isolated regions and organs of the body, the Delcath System, will be highlighted in the October 19, 2007 edition of "Clinica World Medical Technology News," a leading international medical technology news publication. The article profiles Delcath in a discussion of three companies that presented at the 15th Annual BioPartnering Europe conference in London, England last week. Delcath also presented at the Biotechnica Partnering Conference in Hanover, Germany last week, as part of its strategy to meet with major European drug, biotechnology and medical device companies to expand awareness of the Company's unique Percutaneous Hepatic Perfusion Percutaneous Hepatic Perfusion (PHP) is a regionalized, minimally-invasive approach to cancer treatment currently undergoing Phase II and Phase III clinical testing. technology. BioPartnering Europe facilitates partnering and licensing discussions between American, European and Asian biotechnology and pharmaceutical companies. Biotechnica Partnering, a segment of a much larger biotechnology exposition and international trade fair, had attendance surpassing thirteen thousand. Delcath delivered podium presentations at both conferences, and hosted an Open House in London where management introduced the Company and showcased its technology to a select group of conference attendees. Richard L. Taney, President and Chief Executive Officer of Delcath, commented, "Our European presentations were well received and confirmed the clinical potential for the Delcath System overseas. This initial foray into Verb 1. foray into - enter someone else's territory and take spoils; "The pirates raided the coastal villages regularly" raid encroach upon, intrude on, obtrude upon, invade - to intrude upon, infringe, encroach on, violate; "This new colleague invades my the international community, combined with our profile in "Clinica," will enhance the awareness of and expand opportunities for the growth and success of the Delcath System in the global marketplace." The article in Clinica follows a recent article profiling Delcath in New Scientist Magazine. Based on the success of these meetings and the continued progress of Delcath's endeavors, the Company has registered for BioPartnering North America North America, third largest continent (1990 est. pop. 365,000,000), c.9,400,000 sq mi (24,346,000 sq km), the northern of the two continents of the Western Hemisphere. . This conference, in Vancouver, B.C., in February 2008, will provide Delcath the opportunity to continue to build its international reputation as the global leader in percutaneous perfusion technology. About Delcath Systems, Inc. Delcath Systems is the developer of percutaneous perfusion technology for organ- or region-specific delivery of therapeutic and chemotherapeutic agents. The Delcath System is currently being tested with the drug Melphalan in a Phase III Noun 1. phase III - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the FDA trial of patients with metastatic Metastatic The term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. ocular and cutaneous cutaneous /cu·ta·ne·ous/ (ku-ta´ne-us) pertaining to the skin. cu·ta·ne·ous adj. Of, relating to, or affecting the skin. Cutaneous Pertaining to the skin. melanoma in the liver, and a Phase II trial of patients with primary liver cancers and metastatic tumors in the liver from neuroendocrine neuroendocrine /neu·ro·en·do·crine/ (-en´do-krin) pertaining to neural and endocrine influence, and particularly to the interaction between the nervous and endocrine systems. neu·ro·en·do·crine adj. cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. The Company's intellectual property portfolio currently consists of 18 patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website www.delcath.com. The Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 provides a safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion